Stock-Based Compensation for Regeneron Pharmaceuticals (REGN)
Stock-Based Compensation for Regeneron Pharmaceuticals (REGN): headline value $993.70M · YoY +1.1%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingStock-Based CompensationSwitch metric
Latest period
$993.70M
YoY change
+1.1%
5Y CAGR
+18.1%
Peak year (2025)
$993.70M
Latest annual
$993.70M
Stock-Based Compensation history chart for Regeneron Pharmaceuticals (REGN) from 1991 to 2025
Stock-Based Compensation history table for Regeneron Pharmaceuticals (REGN) from 1991 to 2025
| Fiscal year | Period ended | Reported | Stock-Based Compensation | YoY |
|---|---|---|---|---|
| 2025 | $993.70M | +1.1% | ||
| 2024 | $982.80M | +11.1% | ||
| 2023 | $885.00M | +22.1% | ||
| 2022 | $725.00M | +20.5% | ||
| 2021 | $601.70M | +39.3% | ||
| 2020 | $432.00M | -7.0% | ||
| 2019 | $464.30M | +8.6% | ||
| 2018 | $427.40M | -15.7% | ||
| 2017 | $507.28M | -9.4% | ||
| 2016 | $559.88M | +22.0% | ||
| 2015 | $459.05M | +49.4% | ||
| 2014 | $307.24M | +54.9% | ||
| 2013 | $198.40M | +110.7% | ||
| 2012 | $94.16M | +67.9% | ||
| 2011 | $56.09M | +40.6% | ||
| 2010 | $39.90M | +27.6% | ||
| 2009 | $31.26M | -3.9% | ||
| 2008 | $32.52M | +15.8% | ||
| 2007 | $28.07M | — | ||
| 2006 | $0 | — | ||
| 2005 | $0 | — | ||
| 2004 | $0 | — | ||
| 2003 | $0 | — | ||
| 2002 | $0 | — | ||
| 2001 | $0 | — | ||
| 2000 | $0 | — | ||
| 1999 | $0 | — | ||
| 1998 | $0 | — | ||
| 1997 | $0 | — | ||
| 1996 | $0 | — | ||
| 1995 | $0 | — | ||
| 1994 | $0 | — | ||
| 1993 | $0 | — | ||
| 1992 | $0 | — | ||
| 1991 | $0 | — |
Stock-Based Compensation values are taken from Regeneron Pharmaceuticals's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
The 2025 reading of Regeneron Pharmaceuticals (REGN) stock-based compensation is $993.70M – edged up 1.1% year-over-year.
Regeneron Pharmaceuticals stock-based compensation has recorded the values shown across consecutive periods, with a +18.1% compound annual growth rate over 2020–2025 (5 years).
The dataset's maximum stock-based compensation sits at $993.70M (2025); the minimum reading of $0 dates to 1991.
Regeneron Pharmaceuticals (REGN) sits 2nd of 8 Healthcare peers we track on this metric, against a peer median of $313.00M.
Regeneron Pharmaceuticals Stock-Based Compensation by Year
Regeneron Pharmaceuticals Stock-Based Compensation 2025: $993.70M
Regeneron Pharmaceuticals stock-based compensation in 2025 was $993.70M, edged up 1.1% from 2024. This figure represents the highest annual value in the available history.
Regeneron Pharmaceuticals Stock-Based Compensation 2024: $982.80M
Regeneron Pharmaceuticals stock-based compensation in 2024 was $982.80M, grew 11.1% from 2023.
Regeneron Pharmaceuticals Stock-Based Compensation 2023: $885.00M
Regeneron Pharmaceuticals stock-based compensation in 2023 was $885.00M, grew 22.1% from 2022.
Regeneron Pharmaceuticals Stock-Based Compensation 2022: $725.00M
Regeneron Pharmaceuticals stock-based compensation in 2022 was $725.00M, grew 20.5% from 2021.
Regeneron Pharmaceuticals Stock-Based Compensation 2021: $601.70M
Regeneron Pharmaceuticals stock-based compensation in 2021 was $601.70M.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers — Stock-Based Compensation
Companies in the same sector as Regeneron Pharmaceuticals, ranked by their latest stock-based compensation.
| Company | Stock-Based Compensation | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $1.35B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $971.00M | Healthcare |
| AbbVie Inc. (ABBV) | $955.00M | Healthcare |
| Eli Lilly and Company (LLY) | $626.00M | Healthcare |
| AstraZeneca PLC (AZN) | $0 | Healthcare |
| Merck & Co., Inc. (MRK) | $0 | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
| Novo Nordisk A/S (NVO) | $0 | Healthcare |
Frequently asked questions
What is Regeneron Pharmaceuticals's stock-based compensation?
Latest reported stock-based compensation for Regeneron Pharmaceuticals (REGN) is $993.70M (period ending December 31, 2025).
How has Regeneron Pharmaceuticals stock-based compensation changed year-over-year?
Regeneron Pharmaceuticals (REGN) stock-based compensation changed +1.1% year-over-year on the latest annual filing.
What is the long-term growth rate of Regeneron Pharmaceuticals stock-based compensation?
Regeneron Pharmaceuticals (REGN) stock-based compensation compound annual growth rate is +18.1% over the most recent 5 years available.
When did Regeneron Pharmaceuticals stock-based compensation hit its highest annual value?
Regeneron Pharmaceuticals stock-based compensation reached its highest annual value of $993.70M in 2025.
What was Regeneron Pharmaceuticals stock-based compensation in 2024?
Regeneron Pharmaceuticals (REGN) stock-based compensation in 2024 was $982.80M.
What was Regeneron Pharmaceuticals stock-based compensation in 2025?
Regeneron Pharmaceuticals (REGN) stock-based compensation in 2025 was $993.70M.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
REGN Overview
Company profile, financial tools, and key metrics
REGN Revenue Counter
Earns $454.81 every second. See per minute, hour, and day.
REGN Earnings Counter
Earns $142.85 per second net profit. See per minute, hour, and day.
REGN Economic Scale
Exceeds Rwanda's GDP. Compare with world economies.
REGN What If Invested
What if you had invested $1,000? See historical returns from any date.
REGN How It Makes Money
Discover visual breakdown of $14.34B in revenue — where it comes from and where it goes.
REGN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
REGN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
REGN Daily Price Character
Explosive · 47.1% historical win rate (green days). Streaks & record days.
REGN Buybacks
4.33% TTM buyback yield. Shareholder yield & SBC comparison.
REGN Dividend Profile
Yield: 0.52%. See full history.
REGN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
REGN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.